Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REYAGEN: Optimization of unboosted atazanavir dosing with tenofovir
2009-014216-35Phase 4Active
- Sponsor
- ASL TO4
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of atazanavir in human immunodeficiency virus infection (HIV), sponsored by ASL TO4. Primary endpoints: Pharmacokinetic exposure of unboosted atazanavir with tenofovir, Virological suppression at week 48 and 1 more. Started Nov 2009; status: active.
02
Drugs
atazanavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2009-014216-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014216-35.